Royalty Pharma Plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51
Goldman Sachs analyst Chris Shibutani maintains $Royalty Pharma(RPRX.US)$ with a buy rating, and maintains the target price at $51.According to TipRanks data, the analyst has a success rate of 46.3%
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops
Express News | Ascendis Pharma and Royalty Pharma Enter Into $150 Million Royalty Funding Agreement
Insiders At Royalty Pharma Sold US$42m In Stock, Alluding To Potential Weakness